Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study

TY - JOUR

T1 - Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study

AU - Urup, Thomas

AU - Pawlak, W Z

AU - Petersen, P M

AU - Pappot, H

AU - Rørth, M

AU - Daugaard, G

PY - 2013/5

Y1 - 2013/5

N2 - Background:Adrenocortical carcinoma (ACC) is a rare disease with a poor response to chemotherapy. Cisplatin is the most widely investigated drug in the treatment of ACC and in vitro studies have indicated activity of taxanes. The objectives of this study were to evaluate the efficacy and toxicity of cisplatin combined with docetaxel as first-line treatment of advanced ACC.Methods:Patients with advanced ACC were included in this phase II trial investigating the response to a combination of cisplatin (50 mg m-2) and docetaxel (60 mg m-2) administered with a 3-week interval.Results:Nineteen patients were included in this study. The response rate was 21% (95% CI: 3-39%). No patients obtained a complete response, 32% had stable disease, and 37% progressed while on treatment. The median progression-free survival (PFS) was 3 months (95% CI: 0.7-5.3 months) and 1 year PFS was 21% (95% CI: 3-39%). Median survival was 12.5 months (95% CI: 6-19 months). The predominant grade 3/4 toxicity was neutropenia (35%); febrile neutropenia occurred in 5% of cycles.Conclusion:This study could not demonstrate that the combination of cisplatin and docetaxel has higher efficacy than other regimens reported in previous studies.

AB - Background:Adrenocortical carcinoma (ACC) is a rare disease with a poor response to chemotherapy. Cisplatin is the most widely investigated drug in the treatment of ACC and in vitro studies have indicated activity of taxanes. The objectives of this study were to evaluate the efficacy and toxicity of cisplatin combined with docetaxel as first-line treatment of advanced ACC.Methods:Patients with advanced ACC were included in this phase II trial investigating the response to a combination of cisplatin (50 mg m-2) and docetaxel (60 mg m-2) administered with a 3-week interval.Results:Nineteen patients were included in this study. The response rate was 21% (95% CI: 3-39%). No patients obtained a complete response, 32% had stable disease, and 37% progressed while on treatment. The median progression-free survival (PFS) was 3 months (95% CI: 0.7-5.3 months) and 1 year PFS was 21% (95% CI: 3-39%). Median survival was 12.5 months (95% CI: 6-19 months). The predominant grade 3/4 toxicity was neutropenia (35%); febrile neutropenia occurred in 5% of cycles.Conclusion:This study could not demonstrate that the combination of cisplatin and docetaxel has higher efficacy than other regimens reported in previous studies.

U2 - 10.1038/bjc.2013.229

DO - 10.1038/bjc.2013.229

M3 - Journal article

C2 - 23652308

SN - 0007-0920

VL - 108

SP - 1994

EP - 1997

JO - The British journal of cancer. Supplement

JF - The British journal of cancer. Supplement

IS - 10

ER -